Hereditary deficiency of complement component C3 in a 10-yr-old boy was studied. C3 could not be detected by RIA of serum from the patient. Segregation of C3 S and C3 F allotypes within the family confirmed the presence of a null gene for C3, for which the patient was homozygous. 30 exons have been characterized, spanning the entire ft chain of C3 and the a chain as far as the C3d region. Sequence analysis of the exons derived from the C3 null gene showed no abnormalities in the coding sequences. A GT-AT mutation at the 5' donor splice site of the intervening sequence 18 was found in the C3 null gene. Exons 17-21 were amplified by the polymerase chain reaction (PCR) from first-strand cDNA synthesized from mRNA obtained from peripheral blood monocytes stimulated with LPS. This revealed a 61-bp deletion in exon 18, resulting from splicing of a cryptic 5' donor splice site in exon 18 with the normal 3' splice site in exon 19. This deletion leads to a disturbance of the reading frame of the mRNA with a stop codon 17 bp downstream from the abnormal splice in exon 18. His parents had both the normal and abnormal C3 mRNA and were shown to be heterozygous for this mutation by sequence analysis of genomic DNA amplified by PCR. Similar splice mutants have previously been reported in the ft-globin, phenylalanine hydroxylase, and porphobilinogen deaminase genes. This mutation is sufficient to cause the deficiency of C3 in the patient.
Introduction
Complement protein C3 is the major component of the complement system in plasma (-1 g/liter). C3 is synthesized mainly by the liver and in small amounts by activated monocytes and macrophages. It is produced as a single polypeptide of 185 kD, pro-C3, which is then processed by proteolysis to yield the mature protein, consisting of two disulfide-linked subunits, a and fl, of 1 10 and 75 kD, respectively. The C3 gene is located on human chromosome 19 (1) . Cloning of the C3 gene from cDNA revealed that the precursor molecule consists of 1663 amino acids, and that it has significant sequence homology to a2-macroglobulin and C4 (2) . The full organization of the human C3 gene has recently been defined (3, 4) , showing that this gene spans -41 kb and consists of 41 exons.
Inherited deficiency ofC3 has been described in man, dogs, and guinea pigs. C3-deficient dogs show an autosomal codominant pattern of inheritance, and animals heterozygous for the deficiency state have -50% of the mean C3 concentration found in normal dogs (5) . The study of human subjects with hereditary C3 deficiency provides the best evidence for the physiological activities of the complement system in vivo. 15 such individuals (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) have been described, 12 of whom have suffered from recurrent pyogenic infections, which emphasizes the important physiological role of C3 as an opsonin for bacteria. Two patients have developed mesangiocapillary glomerulonephritis (7, 10) , and three hematuria and/or proteinuria ( 14) . It has been proposed that this association with nephritis is due to failure of a second physiological activity of the complement system, that of promoting the disposal of immune complexes to the mononuclear phagocytic system (16) .
There is evidence for genetic heterogeneity in the molecular basis of C3 deficiency. Small amounts of circulating C3 were identified in the sera from some patients with C3 deficiency (9) , but in others no C3 was detected at all (17) . In this paper, we report the molecular basis for C3 deficiency in a patient with homozygous deficiency. We found that an unusual RNA splicing abnormality results in a deletion of 61 nucleotides with a stop codon 17 bases downstream of the abnormal splice site.
Methods
Complement assays. Antigenic concentrations ofCl q, C2, C3, and C4 were measured by single radial immunodiffusion. CH50 was estimated by a modification of the method of Mayer (18) . Alternative pathway and factor B activities were measured by a hemolytic plate assay as described (18) . Nephritic factor was measured as previously described (19) . An RIA was developed for quantitation of C3 using an mAb against C3d (clone 3; gift of Prof. P. J. Lachmann, Medical Research Council, Molecular Immunopathology Unit, Cambridge). The antibody, at 10 ,ug/ml in PBS, 10 mM NaN3, 0.05% Tween-20, pH 7.3 was coated on wells of polystyrene microtitre plates (Dynatech, Billingshurst, Sussex, England). The plates were blocked with PBS, 10 mM, NaN3, 0.05% Tween-20, 1% BSA, and then incubated with dilutions of sera. Polyclonal affinity-purified goat anti-C3 antibody was labeled with 125I to a specific activity of 1-2 ,uCi/ug and used to probe the microtiter plates at a final concentration of 20 ,g/ml. The sensitivity of the assay was 60 ng C3/ml. Purified C3 for assays of reconstitution of hemolytic activity of the patient's serum was kindly donated by Prof. G. D. Ross (University of North Carolina, Chapel Hill). C3 allotyping was performed by high-voltage agarose gel electrophoresis using a modified version of the method of Teisberg (20) .
Preparation and analysis of genomic DNA. Genomic DNA was isolated from whole blood. 10 5 ,g/ml in medium alone. mRNA was harvested using the guanidinium isothiocyanate/cesium chloride method (24) and Northern blot analysis was performed using the pC3.11 cDNA clone as a probe. Liver mRNA was used as a positive control. The same filters were also hybridized with an a-tubulin probe (25) as an RNA control.
Construction and screening ofgenomic library. Genomic DNA isolated from a B-lymphoblastoid cell line, transformed by Epstein-Barr virus, from the patient was partially digested with Sau3A I, and fragments were separated by electrophoresis in a 0.6% low-melting point agarose gel (Bethesda Research Laboratories, Gaithersburg, MD). DNA fragments sized between 10 and 23 kb were isolated and ligated to lambda EMBL-3 vector, and packaged in vitro (26). 1.5 million recombinants were screened using two probes, pC3.11 and pC3.59 (22) , spanning the full length of the human C3 cDNA. Recombinant phage from large-scale lysates was purified by equilibrium centrifugation in cesium chloride density gradients and DNA was extracted from phage particles (24) .
Restriction mapping and DNA sequencing. Restriction maps of the lambda clones were obtained after single and double digests with restriction enzymes and Southern blot analysis using the C3 cDNA clones as probes. Specific exon-encoding genomic fragments were subcloned into the plasmid PUC 18 for detailed analysis. DNA sequencing was performed by the dideoxy-termination method (27) using I unit of Taq polymerase (Perkin-Elmer Cetus Corp., Norwalk, CT). 30 cycles ofthe reaction were performed at 94°C for 2 min, 56°C for 2 min, and 72°C for 2 min. The amplified DNA was subcloned into Sma I-digested Ml 3mp8, and sequenced as described above.
cDNA synthesis and PCR amplification. First-strand cDNA synthesis was performed as reported (28) using 2 ,g of total mRNA obtained from monocytes-derived macrophages stimulated with LPS, as previously described, from the C3-deficient patient, his mother and a normal subject. Amplification of cDNA was then carried out using PCR by addition of 2. 
Results
Complement investigations andfamily study. The CH5o of the patient was 42 U/ml (normal control pool 2,512 U/ml). Alternative pathway activity was < 10% of normal pooled serum (NHS). Functional factor B activity was 112% of NHS. The antigenic concentrations of the following complement proteins were: Clq 75%, C2 57%, C4 55%. No C3d was detected in the patient's serum and assay for C3 nephritic factor was negative. C3 was not detected using a radioimmunoassay with a sensitivity of 60 ng C3/ml. The addition of purified C3 to the patient's serum to a final concentration of 1 g/liter restored the CH50 to 2,010 U/ml.
The results of C3 allotyping studies and measurement of serum C3 concentrations of the family members are shown in Fig. 1 , which demonstrate the existence of a null C3 gene (C3*QO [quantity 0]) within the family. The patient's maternal grandfather was C3 FS and his grandmother C3 S. Two oftheir children were allotyped: the patient's mother who was C3 S and her brother, who was C3 F alone. This latter individual must therefore have inherited a C3*QO allele from his mother, whose genotype must therefore be C3 S*QO, and the segregation of this C3*QO allele was confirmed by measurements of antigenic levels of C3 amongst the family members (Fig. 1) .
Genomic organization of the C3 null gene. Southern blot analysis of DNA from the patient and family members after digestion with eight different restriction enzymes and using a C3 cDNA probe showed no structural difference between the C3 null gene and normal allelic variants (data not shown). We therefore constructed and screened a genomic library derived from the patient using pC3. 11 and pC3.59 as probes, and isolated five positive clones ranging in size from 9 to 17 kb. Mapping of these genomic clones showed that they spanned the ,B chain, from amino acid 259, to the 3' end of the a chain. 18 (3) . This alters the consensus GT dinucleotide to AT (Fig. 2) . In order to verify that this finding was not caused by a cloning artefact, two 2 1-mer oligonucleotides, EX 18 and EX 19, plementary to sequences in exons 18 and 19, were constructed and used to amplify genomic DNA by PCR. Amplified DNAs were sequenced, and the results showed that both parents of the patient were heterozygous for the normal and abnormal 5' splice sequence. Sequences over the same region from two normal individuals showed the normal 5' donor splice site consensus sequence of GT. All the other 22 5' exon-intron boundaries were identical to the consensus sequences found in the normal C3 gene (3); the 23 3' intron-exon boundary dinucleotides were all AG.
Abnormal splicing ofthe C3 null gene. Preliminary studies by the technique of Northern blotting of C3 mRNA obtained from peripheral blood monocytes stimulated by LPS suggested an absence of C3 mRNA production in the patient. However, these results were not conclusive due to difficulties with obtaining sufficient peripheral blood to prepare large numbers of monocytes. We therefore took the following approach to analyze C3 mRNA in the patient. We performed a first strand cDNA synthesis and we used this as template for PCR amplification of target sequences encoding different regions of the C3 molecule.
Amplification of the region spanning exons 17-21 (using Oligos EX 17 and EX2 1 as primers) from the patient generated a product that was smaller in size than that found in the normal subject (Fig. 3) . Both the PCR products were detected from the cDNA of the patient's mother, who was shown to be heterozygous for the splice site mutation at the genomic level. A ratio of -4:1 between the normal and the abnormal message was calculated by scanning with a densitometer the autoradiograph of Southern blot probed with Oligo EXl9, corresponding to a region in the middle of exon 19 (Fig. 4) . On sequencing the abnormal fragment from the patient, a 61 -nucleotide deletion of the normal cDNA sequence was found (from nucleotides 2,354-2,414) and results in the joining of part of exon 18 to exon 19. This mRNA sequence is out ofthe normal translation frame distal to the abnormal splice and generates a stop codon (TGA) 17 bp downstream in exon 19 (Fig. 5) . A cryptic donor splice consensus sequence (GTGAGT) was identified within exon 18, 5' to the site of the abnormal splice. Amplification of two other regions of the cDNA 5' and 3' to the splice site mutation (spanning exons [3] [4] [5] [6] [7] [8] in the f3 chain and exons [28] [29] [30] in the a chain) generated products of identical size in both the patient and the normal subject (Fig. 3) .
We also amplified and sequenced the cDNA ofthe C3 null gene from the signal peptide to amino acid 263 to verify the possibility of further mutation upstream from the splice site mutation. The size of PCR-products were 445 (Oligos EX1 and EX4) and 543 bp (Oligos EX3 and EX8), identical to the normal subjects. No differences in the sequences of these fragments were found when compared with the published cDNA. The autoradiograph is read from the top downwards and the alphabets G, A, T, C, refer to nucleotides guanine, adenine, thymine and cytosine respectively. Sequences from the patient's amplified DNA showed a 61 -nucleotide deletion and a stop codon, TGA (shown within the rectangle), 17 bases downstream. Numbering of the nucleotides is according to the published C3 cDNA (22) . Figure 3 . Agarose gel electrophoresis of PCR products. Amplified products from C3 cDNA derived from LPSstimulated monocytes were reamplified before electrophoresis on a 2% agarose gel. The No C3 protein was detected using a radioimmunoassay with a sensitivity of 60 ng/ml. It should be noted that a previous study (9) demonstrated C3 concentrations between 17 and 58 ng/ml in the sera of three other unrelated caucasoid C3-deficient patients, levels that are below the detection limit of the present assay. However the studies of the gene structure and mRNA expression in our patient suggest (31) (32) (33) in the f3-globin gene, causing fl-thalassaemia; in the phenylalanine hydroxylase gene, causing phenylketonuria (34) ; and in the porphobilinogen deaminase gene, causing acute intermittent porphyria (35) . The effects of naturally occurring mutations in the canonical GT 5' donor splice junction dinucleotide on RNA processing and subsequent protein expression are variable. In phenylketonuria there is a GT-AT mutation at the 5' donor splice site of exon 12. The transfected abnormal phenylalanine hydroxylase gene directed aberrant splicing of exon 11 to exon 13 of precursor RNA. This resulted in production of a dysfunctional, unstable, and truncated protein lacking 52 amino acids (36) . Two abnormal RNA transcripts were produced in vitro in the case of the GT-AT mutant at the 5' donor splice site of IVS 2 of the cloned and transfected f3-globin gene (33) . Neither encoded fl-globin protein in vitro or in vivo. In vitro mutations of the 5' donor splice site dinucleotide in the rabbit f3-globin gene from GT to AT showed that although 5' cleavage occurs correctly with reduced efficiency, there is abnormal 3' cleavage and accumulation of lariat intermediates (37) .
The presence of a small amount of haemolytic activity measured by CH50 (1.6% of normal) may be due to a small amount of C5 cleavage by C42 occurring in the absence of C3 as previously suggested by Kitamura (17) . It seems clear that this patient has an absolute deficiency of C3 on the basis ofthe evidence presented here. It is therefore of interest that he is extremely fit and has attained the normal physical and intellectual milestones of a 10-yr-old boy. Apart from repeated upper respiratory tract infections and associated rashes as a young child, largely controlled by the administration of prophylactic antibiotics, he is well.
In conclusion, we have presented a molecular explanation for a case of total deficiency of C3. Studies of such patients provide the clearest opportunity to ascertain the physiological activity of C3 in vivo.
